Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ask here:
http://purthanol.com/Contact.html
http://whois.polodomains.com/domain/nay2oWJCf47-BE9SkNyigQ.._info.html
Domain Name: PURTHANOL.COM
Created on: 06-Apr-12
Expires on: 06-Apr-15
Last Updated on: 06-Apr-12
Administrative Contact:
stella, leonard Email of leostella
global biotech corp
5800 metropolitan east
suite 328
montreal, Quebec h1s1a7
Canada
+1.5143334545
Technical Contact:
stella, leonard Email of leostella
global biotech corp
5800 metropolitan east
suite 328
montreal, Quebec h1s1a7
Canada
+1.5143334545
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778492/
it is the last I find:
"Synlett. Author manuscript; available in PMC 2010 February 11.
Published in final edited form as:
Synlett. 2009 February 11; 9: 1517–1519.
doi: 10.1055/S-0029-1217183
PMCID: PMC2778492
NIHMSID: NIHMS140846
Synthesis of the Naturally Occurring (–)-1,3,5-Tri-O-Caffeoylquinic Acid
Kay M. Brummondcorresponding author and Jolie E. DeForrest
Author information ? Copyright and License information ?
Go to:
Abstract
Ribonuclease H (RNase H) is an essential component to the replication of human immunodeficiency virus (HIV), and only a few inhibitors of this enzyme are known. Millenia Hope Pharmaceuticals Inc. found that (–)-1,3,5-tri-O-caffeoylquinic acid is a potent RNase H inhibitor and antiviral agent. A facile route leading to this inhibitor from commercially available (–)-quinic acid is reported within.
Keywords: reverse transcriptase, ribonuclease H, (–)-1,3,5-tri-O-caffeoylquinic acid, (–)-quinic acid
An estimated 33.2 million people worldwide are living with human immunodeficiency virus (HIV). In 2007, 2.5 million people were newly infected with HIV and 2.1 million deaths were attributed to acquired immune deficiency syndrome (AIDS). These epidemic numbers, coupled with studies of the most promising HIV vaccine candidate being halted in 2007, have led to an increased need for therapies that attack HIV via novel mechanisms of action.1
Replication of the HIV genome is carried out by HIV-1 reverse transcriptase (RT), an enzyme displaying both DNA polymerase and ribonuclease H (RNase H) activities. While RNase H is essential to viral function, only a few inhibitors have emerged and none are in clinical trials.2,3
Recently, Millenia Hope Pharmaceuticals Inc. isolated 1,3,5-tri-O-caffeoylquinic acid (1, Scheme 1) from cultured plant cells. They subsequently found 1 to be a potent RNase H inhibitor and antiviral agent (IC50 = 0.4 µM) using a cellular assay consisting of human peripheral blood mononudear cells (PBMC) infected with HIV-1.4 The naturally occurring polyphenol 1 was previously reported by Okuda and co-workers who isolated compound 1 from the fruit of Xanthium strumarium L., a fruit that has been used for medicinal purposes in both China and Japan.5 The intriguing biological activity of 1,3,5-tri-O-caffeoylquinic acid, and access to suitable quantities of compound for further biological evaluations and mechanistic studies, motivated the synthesis of this compound. Furthermore, an understanding of the structure–activity relationship (SAR) required for RNase H inhibition and antiviral activity can be gained by analog synthesis.
....."
http://www.idm.pitt.edu/directory/bios/parniak.asp
http://www.researchgate.net/researcher/48106245_Michael_S_Parniak
http://search.engrant.com/project/3rHGN6/hiv_rnase_h_natural_product_inhibitors
http://www.thefreelibrary.com/Millenia+Hope+Acquires+AIDS+Patent.-a0142623652
http://www.highbeam.com/doc/1G1-164609432.html
http://www.researchgrantdatabase.com/g/5U19AI073975-02/HIV-RNase-H-natural-product-inhibitors/
http://www.ncbi.nlm.nih.gov/pubmed/22252812
http://www.natap.org/2009/CROI/croi_83.htm
http://investing.businessweek.com/research/stocks/people/person.asp?personId=26321941&ticker=MLHI
Bahige Baroudy Ph.D.
Scientific Consultant and Member of the Scientific Advisory Board, Millenia Hope Inc.
Corporate Headquarters*
1250 Rene Levesques West
Montreal, Quebec H3B 4W8
Canada
Phone: 514-846-5757
Fax: 514-935-9758
HISTORY
http://www.hotstocked.com/companies/m/millenia-hope-inc-MLHP-description-62910.html
Company Description
(a) Business Development
Millenia Hope Inc., a Delaware corporation, was organized on December 24, 1997. The Company has not been involved with any bankruptcy, receivership or similar proceedings. The Company has not had any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business.
(b) Business of Issuer
MILLENIA was formed to further develop and distribute an anti-malarial agent called MALAREX/MMH(TM)18 (the "Product"). As disclosed later, the Company has also filed further patent applications for indications besides malaria, and another patent application for multi-drug resistant strains of malaria.
Millenia's goal as a biopharmaceutical corporation is to both purchase and develop patented drugs dealing with infectious diseases specifically, but not exclusively, anti-malarial agents. To date, the Company has had only insignificant sales. Further, internally generated funds may not be sufficient to fund the operation of the Company for the upcoming fiscal year. However, the officers and directors have committed to fund the operations of the Company for the next fiscal year, should there be any shortfall. (See note 3 of the financial statements)
MALARIA, THE DISEASE
Malaria is predominant in four regions of the world: Africa India South East Asia Central and South America
Malaria is one of the most debilitating diseases in the developing world today. Once thought to be virtually eradicated, malaria has resurfaced to affect over 500 million people annually. And that is only the reported cases. It is suspected that the reported cases may represent less than one third of actual existing cases. It is now known that mosquitoes have not only been able to develop an immunity to the chemical insecticides used to control breeding but, they have also developed resistance to many of the most commonly used anti-malarial drugs on the market today.
Malaria is a disease that is caused by a parasite that involves the red blood cells of humans. The parasites are ingested, primarily, by the female mosquito when feeding on an infected person's blood and then spread when biting another person. Once inside the mosquito, the parasites migrate to the salivary glands where they are free to be transmitted with the next bite.
Four species of malaria parasites cause disease in humans:
Plasmodium vivax P. Malariae P. Falciparum P. Ovale.
The World Health Organization estimates that some 500 million people each year are affected by malaria. The effect that malaria has on the world is truly devastating, particularly on women. Malaria accounts for almost 3 million deaths, a large portion of which are children. Children are dying from malaria at the rate of 20,000 a week. Malaria is a major cause of death in first-time mothers and is the leading cause of death of African children under the age of 5.
P. Falciparum is the most common and causes the majority of deaths, accounting for approximately 90% of African and about 50% of India, South East Asia and
Latin America malaria cases. P. Falciparum is the form of malaria that Millenia Hope is working to combat, accounting for approximately 55-60% or 275-300 million of the known cases of malaria and approximately 850,000 - 1,500,000 deaths.
The economic losses affected with malaria are estimated at US$ 12 billion annually and if the trend is not reversed will soon continue to escalate. A single bout of malaria is estimated to cost a sum equivalent to 10-20 working days in India or Africa.
CURRENTLY AVAILABLE TREATMENTS
In the pursuit of the eradication of malaria, scientists and researchers have developed many different drugs to battle the parasite. As the parasite develops a resistance to an earlier generation of medications, researchers must continue to look for other drug combinations that will be effective in controlling the disease.
As per the Malaria Foundation International (2004), malaria now kills more people than it did 3 decades ago. The WHO has made the roll back of Malaria, by 50% during the decade ending 2011, one of its 4 major objectives of the current decade.
Quinine, a natural product from the bark of the cinchona tree, was one of the first treatments for malaria and appeared in the 17(th) century. It is still effective but can be toxic. Quinine remained the drug of choice for treatment and prevention until 1942 when it was replaced by chloroquine. With widespread chloroquine resistance, quinine together with artemether have once again become an important treatment for malaria.
Chloroquine (Aralen is the brand name of Sanofi Synthelab Inc.) , was first used in the 1940's and is a weekly treatment. Today it is manufactured by all the major pharmaceutical companies. The first cases of resistance were found in South America and South East Asia in the early 60's and it is now practically ineffective almost everywhere. However it is still the most widely used anti-malarial treatment in Africa as it is the cheapest drug available.
Sulfadoxone / pyrimethamine (Fansidar is the brand name of Roche), was developed in the 1960's. The treatment consists of three doses taken together in one day. Today, this drug is manufactured by a number of pharmaceutical companies; the Fansidar trademark belongs to Hoffman LaRoche. Despite widespread resistance in South East Asia and parts of South America, it is starting to become the first line of treatment in some African countries where chloroquine resistance is even more widespread.
Mefloquine (Lariam is the brand name of Roche), was developed by the U.S. army in the early 1980's and commercialized by Hoffman LaRoche. Resistance has been observed since the early 1980's, particularly in the South East Asian countries.
Halofantrine, was also developed by the U.S. army and marketed by SmithKline Beecham. In the 1990's, cross-resistance with mefloquine and side effects (sometimes severe) have been observed.
Artemisinins, (derived from an ancient Chinese herbal remedy) comprise a family of products. The two compounds most widely used, mainly in South East Asia, are artemether and artesunate, They are not yet widely used in part due to toxicity fears. Due to the high rate of treatment failures, artemisinins are now also being combined with other anti malarial agents and are becoming one of the drugs of choice.
Currently, drugs based on new compounds are being tested. The aforementioned information was reported in the Malaria Foundation Fact Pack, updated as of February 2004, Section 8. The Fact Pack can be found at www.malaria.org.
An analysis of the current problems being experienced with the available drugs as listed by the Malaria Foundation Fact Pack and summarized above leads to the conclusion that all of the above families of anti-malarial agents have the same problem in common: the resistance developed by malaria to a greater or lesser degree to each of the above mentioned drugs.
As per a study done by the Center for Disease Control (CDC) in Atlanta, Georgia, (2001),
there is up to 70% resistance (recent studies show upwards of 75% resistance) to three most commonly used anti-malarials in West Africa, Chloroquine, Sulfadoxone and Mefloquine. It is imperative to develop new anti-malarial drugs to fight the problem of parasitic resistance to the drugs currently being used. As of 2004 the WHO issued an edict to its constituent agencies to stop funding chloroquine, sulfodoxone and mefloquine, due to their ineffectiveness based on their parasitic resistance problem.
PRODUCT HISTORY
MALAREX/MMH(TM)18
The refining process of MALAREX/MMH(TM)18, using the species called Peschiera found in Brazil, was successfully implemented by the research team of Rossi and Motta in 1997. Thereafter, Millenia bought all rights to MALAREX/MMH(TM)18 from the co-owners of the patent applications, Mr. Rossi and Mr. Motta on January 7, 1998. As of February 28, 2006, Millenia has been given the authorization to sell MALAREX/MMH(TM)18 in 18 West African countries, Guinea (Conakry), and Congo (Brazzaville), Togo, Burundi, Central African Republic, Benin, Gabon, Chad, Niger, Mali, Senegal, Democratic Republic of Congo, Guinea (Equatorial), Cameroon, Ghana, Sierra Leone, Mauritana and Burkino Faso as well as the Caribbean nation of the Dominican Republic.
Extracted from natural sources, MALAREX/MMH(TM)18 is not a synthetically derived drug. MALAREX/MMH(TM)18 has had successful tests in the treatment of malaria and is continuing with further ongoing tests to bolster its scientific platform, to further validate its safeness, to allow it to continue to receive further selling authorizations and to improve the efficacy and usefulness of the product.
Throughout in-vitro (cultured cell-tests) and in-vivo (live trials) tests (see Test Results), no serious side effects were detected. When treated with MALAREX/MMH(TM)18 there was no need to take post treatment vitamins or other additives for restructuring the immune system. Moreover, because of its immune-modulatory properties (see test results - Journal of Natural Products vol. 57 November 1994), the extract is non-allergenic and non habit forming. Currently, MALAREX/MMH(TM)18 (active ingredient-Voacamine) is produced in capsule form.
Millenia continues to have regular commercial access to Voacamine processed by producers in Southern Brazil and does not foresee any supply shortages in the near future. Even though Millenia does not have exclusive acess to Voacamine, there are no problems in acquiring Voacamine commercially from producers in the region to satisfy its needs. The encapsulation and packaging of MALAREX/MMH(TM)18 is done by Ropack, a HACCP, cGMP and ISO 9002 firm in Montreal, Canada.
MARKET SIZE
According to the World Health Organization (2002), malaria risks of varying degrees exist in 100 countries and territories. Estimates of populations at risk within these 100 countries total in excess of 2.3 billion people or 40% of the world's population.
The WHO estimates 1.5-2.7 million deaths from malaria of which approximately 850,000- 1,500,000 are caused by P. Falciparum. In addition to the reported cases of contracted malaria, control programs dispense medication for the prevention of malaria in the amount of a further 70 million plus complete treatments annually.
The WHO estimates that for each clinical case reported, there exists at least one, possibly two, that are unreported. Relative to the enormous number of infected humans, it would be virtually impossible to eradicate the disease altogether. If the disease was better controlled prevention, rather than treatment, would become the dominant control factor.
Estimates of expenditures on treatment for the control and prevention of malaria are in excess of US$10 Billion annually. The World Bank, per its figures, allocates US$ 2.5 Billion to third world countries for treatments of insidious African disease, specifically malaria.
DISTRIBUTION AND PRICING
Millenia's objective is to see that MALAREX/MMH(TM)18 is made available to as many people, as quickly as possible. In order to accomplish this goal, Millenia will initially rely upon already existing distribution networks. Millenia intends to make MALAREX/MMH(TM)18 available at prices that are, for a new anti-malarial agent with no parasitic resistance, competitive with the cost of other comparable drugs currently used in the treatment of malaria. This, and MALAREX/MMH(TM)18's lack of harmful side effects, will facilitate MALAREX/MMH(TM)18 'S entry into the marketplace. Within this pricing structure, the Company will generate earnings that will allow for future growth and a substantial return on our stakeholders' investment.
Millenia is currently poised to begin selling MALAREX/MMH(TM)18 in significant quantities. To this end, it has already made its initial sales of MALAREX/MMH(TM)18 in Africa, in 2005.
PATENTS AND INTELLECTUAL PROPERTY (IP)
The Millenia Hope IP portfolio applies to two patents; MALAREX/MMH(TM)18 and treatment for multi-drug resistant strains. The Company's portfolio covers the active ingredients from the peschiera plant extract. Based on discoveries in the development program, the Company has submitted a global patent covering a profile of active ingredients from the plant, and the additional clinical properties of the product, namely anti-parasite, anti-viral and antibacterial activities. Today, the patent is in the international phase.
The second US patent application was filed in 2005 covering the treatment and prevention of multi-drug resistant strains of malaria utilizing Millenia Hope's products.
As well, Millenia has received its registered use and trademark for MALAREX/MMH(TM)18.
TEST RESULTS
As reported in a study in the Journal of Natural Products Vol. 57 November 1994, under the auspices of the College of Pharmacy of the University of Illinois at Chicago, Voacamine acted to enhance the growth inhibition of multi-drug resistant cytotoxic cells present in certain malignant diseases such as Hodgkins.
Efficacy, Non-Toxicity Studies
Toxicity In-Vitro Study - University of La Spienza Rome, Institute of Superior Health of Rome - 1997 (Prof C. Galeffi, Prof. M. Nicoletti, Dr. P. Olliafo, Dr. L. Turchetto and the World Health Organization)
- IC 50 level reached at extremely low doses (proof of very low or non-toxicity levels)
Clinica Ospedada diAnchilo, Napula, Mozambique
- IC 50 level reached at very low doses of Voacamine
Efficacy In-Vitro, Ex-Vivo Study - McGill University Health Centre - 2000 (Professors Erwin Schurr, Di Flumeri)
- Substantial decrease in parasite replication and growth.
Toxicity In-Vivo Study (Sprague - Dawley rats) - ITR Laboratories - 2001
- Single oral administration of MMH MALAREX(TM) - free of harmful effects at the very high dosage level of 2000 mg/kg.
Clinical Trials
Trial done by Dr. Francesco du Chaira - Clinic Ospedale di Anchilo, Nampula, Mozambique: (Initial proof of concept)
- 1998 - 74 patients suffering from Falciparum Malaria
- 67 patients were completely cured after 4 days of treatments.
Trials done by Professor Same Ekobo, National Coordinator of Cameroon's Anti-Malarial Program and Director of the Center for Parasite Research in Yaounde, Cameroon, West Africa:
Initial trial to establish treatment dosage levels (equivalent To Phase IIa)
- November 1999 - 30 patients suffering from acute Falciparum Malaria.
- 18 patients were completed cured after 4 days of treatments.
- 12 patients - suffering from extremely elevated parasitic levels, saw a significant
- reduction from their previous levels.
- Side effects, 2 cases of nausea.
Follow-up trials (equivalent to phase IIb)
- September 2001, 17 patients suffering from acute Falciparum Malaria.
- All 17 patients were completely cured after 4 days of treatments.
- Side effects - 1 case of diarrhea, 1 of headache and 1 of dizziness.
- November 2001, 30 patients suffering from acute Falciparum Malaria
- All 30 patients were completely cured after 4 days of treatments.
- Side effects 1 case each of dizziness, headache and vomiting.
- 96.6% of the patients were ready to take MALAREX/MMH(TM)18 again should they incur another episode of malaria.
- November 2003, 102 patients suffering Falciparum Malaria
- Comparative test with Camoquine-quinine based established anti-malarial
- Positive results achieved vs. Camoquine in both efficacy and lack of negative side effects.
Trial done by Max Koula, National Co-ordinator of the Republic of Central Africa's anti-malarial program, Dr. Etienne Fernand Gbagba, Chief of Emergency Medical Services at Community Hospital in Bangui, Republic of Central Africa and Dr. Wilfred Nambei, an immunologist and the head of Parasitology and Microbiology at the University of Bangui.(equivalent to phase III)
- February 2004, 31 patients suffering Falciparum Malaria
- 93.5% of the patients exhibited positive clinical responses (per WHO guidelines) after 5 days of treatments
- Side effects - slight cases of dizziness, earaches and vomiting
Trial done by Dr. Soriba Cisse (equivalent to Phase III)
- In September 2005 Millenia Hope enrolled 230 persons in a trial at the Coca Cola facility in Guinea (Conakry), Africa. This trial, utilizing World Health Organization (WHO) approved protocols in a closed testing environment, was administrated by Dr. Soriba Cisse and staff from the Clinique Pasteur in Guinea (Conakry). Dr. Cisse is the Vice-President, Research and Development, for Millenia Hope. Of the 230 persons enrolled, 55 had malaria and all 55 (100%) were cured within 3 days of taking MALAREX/MMH(TM)18. The patients were monitored for 28 days and there was no recurrence of malaria in any of the patients, even though this is a high risk malaria region.
Upcoming trials
MALAREX/MMH(TM)18 for children will be tested in a pediatric study of children, from 5-17 years of age, that have non-complicated malaria. This study will being conducted by Dr. Nambei in RCA, using World Health Organizations (WHO) protocols and monitored by the regional WHO and the Pasteur Institute. The trial will utilize a new formulation of our pediatric product to replace a previous formulation that had unsuccessful results in RCA in 2005.
We are also planning a large scale trial in Benin (equivalent to Phase III) in conjunction with a Benin NGO. This test will also be run utilizing WHO protocols and under the supervision of the regional WHO.
GOVERNMENT REGULATIONS
In order to safeguard their citizens, governments around the globe require extensive proof that a new drug is completely safe, within statistical parameters, before allowing it into the marketplace. Millenia, being cognizant of the above and of its own responsibility to the public, has collated the extensive laboratory and research data as well as the live trial tests for MALAREX/MMH(TM)18 pursuant to its receiving the designation as a prescription drug.
As well, all countries require certain protocols be followed in order to grant selling authorizations for a pharmaceutical product. Millenia Hope has followed those protocols and procedures and has received 19 country selling authorizations, to date. Several other requests for selling authorizations are pending and Millenia expects a positive response in those cases, as well.
PRODUCT LIABILITY
Any drug or pharmaceutical product poses, by its nature, some level of risk. Since drugs are widely disseminated among populations, all precautions must be taken to ensure that the potential risk of any drug is kept to the barest minimum. Since MALAREX/MMH(TM)18 is an all natural products and not chemically produced, its potentially damaging side effects are minimized. This does not mean that no side effects might occur, even with the most rigorous testing standard applied, but rather that by their nature this compound is inherently less susceptible. This being noted, as the product has been authorized for use as an anti-malarial drug in 19 countries, and has just entered the commercialization phase, the Company is negotiating with several liability insurance carriers to obtain the appropriate liability and product insurance commensurate with the statistical risk factors.
I`m german, if I could, I would telefone.
Thank`s for your activity.
This it is what I found:
(Millenia and globalbiotech seems, is identic contact)
http://www.bioportfolio.com/corporate/company/28081/Millenia-Hope.html
Location
4055 Ste. Catherine West, Suite 151
Montreal
Quebec
H3Z 3J8
Canada
Contact
Phone: (514) 846-5757
Fax: (514) 935-9758
Email: leostella@milleniahope.com
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=28602793
500 Cartier Boulevard West
4th Floor
Laval, QC H7V 5B7
Canada
Phone:
514-288-8822
Fax:
514-935-9758
http://www.otcmarkets.com/stock/MLHI/company-info
Contact Info
2711 Centerville Rd.
Suite 400
Wilmington, DE 19808
Phone: 514-953-7095
http://www.globalbiotechcorp.com/drivingdirections.html
2711 Centerville Rd.
Wilmington Delaware 19808
USA
Contact Info
2711 Centerville Rd.
Suite 400
Wilmington, DE, 19808
tel: 302 288 0658
email: info@globalbiotechcorp.com
"State of the Corporation: Reinventing Millenia Hope -- the New Objective
GlobeNewswirePress Release: Millenia Hope Inc. – Fri, Sep 23, 2011 3:00 PM
MONTREAL and WILMINGTON, Del., Sept. 23, 2011 (GLOBE NEWSWIRE) -- Mr. Leonard Stella, Chairman & CEO of Millenia Hope Inc. (Frankfurt:MLFN.F - News) (Pink Sheets:MLHI), has set out a new direction for the company. "Our strategic planning involved an assessment of the past and the construction of a brighter future. We intend to continue with our infectious diseases platform but will place greater emphasis on the development of new nutraceutical products that will render the company profitable. We have been subjected to certain malicious, unfounded allegations in the press and the bankruptcy of our subsidiary company but have emerged with a renewed sense of purpose, looking forward. Management has decided that we will change the name of the company to emphasize and highlight its new direction. We have been working in collaboration with other pharmaceutical and nutraceutical companies and positive results are on the horizon. We expect to post our financial statements shortly and make the company OTC current in its financial disclosures. We have a moral responsibility to our shareholders to persevere and prosper. Over the past weeks 26 million shares of Millenia Hope have been traded, showing continuing interest in our Company. We have been working quietly and diligently to get the company back on track and bring value to our shareholders. We look forward to the transformation of Millenia Hope into a vibrant and viable company with new goals and objectives."
ABOUT MILLENIA HOPE INC:
Millenia Hope develops innovative treatments and products that enhance the quality of life. The company has put in place programs to fight major infectious diseases and promote healthier lives and is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
SAFE HARBOR STATEMENTS:
This press release may contain forward-looking statements that involve risks and uncertainties, which may include statements about business strategy and development plans, plans for entering into new business, anticipated sources of funds, including the proceeds from future operations, and plans, objectives, expectations and intentions contained in this Press Release that are not historical facts. When used in this Press Release, the words "expects," "intends," "projects," "plans," "believes," "seeks," "estimates" and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risk and uncertainties, actual results could differ materially from those discussed in this Press Release.
Contact:
Mr. Yehuda Kops
Chief Operating Officer
info@milleniahope.com
1-302-357-3638"
http://www.researchgrantdatabase.com/g/5U19AI073975-02/HIV-RNase-H-natural-product-inhibitors/
http://www.newswire.ca/en/story/63717/millenia-hope-inc-receives-a-grant-from-the-national-institutes-of-health-usa-to-develop-new-hiv-therapeutics-in-consortium-with-the-university-of-pit
http://www.ncbi.nlm.nih.gov/pubmed/22252812
http://www.idm.pitt.edu/directory/bios/parniak.asp
http://search.engrant.com/project/3rHGN6/hiv_rnase_h_natural_product_inhibitors
http://www.globalbiotechcorp.com/
http://www.globalbiotechcorp.com/aquaboost.html
http://www.globalbiotechcorp.com/petboost.html
http://www.globalbiotechcorp.com/femtraeffect.html
http://www.globalbiotechcorp.com/pharmateckinternationalltd.…
http://www.globalbiotechcorp.com/newsandevents.php (lebt noch)
http://www.globalbiotechcorp.com/blog.php
http://femtra.com/
https://twitter.com/Aquaboost
http://www.pharmateck.com/servicesoffered.html
http://www.pharmateck.com/productline/clitlmusmaximus.html
http://purthanol.com/Contact.html
http://purthanol.com/Technology___Growth.html
https://twitter.com/Purthanol
http://whois.polodomains.com/domain/nay2oWJCf47-BE9SkNyigQ.._info.html
(stella, leonard and globalbiotechcorp)
http://purthanol.com/Company_at_a_Glance.html
http://business-bankruptcies.com/cases/freedom-environmental-services-inc
"...
Aug 16 #9 Notice of Non-Evidentiary Initial Status Conference Hearing . Hearing scheduled for 9/25/2012 at 02:00 PM at Orlando, FL - Courtroom B, 5th Floor, 135 W. Central Boulevard. (Henry, Mary) (Entered: 08/16/2012)"
Form 8-K
Freedom Environmental Services, Inc. - FRDM
Filed: September 04, 2012 (period: September 04, 2012)
Report of unscheduled material events or corporate changes.
As used in this report, the terms "we", “us", “our", “our company," or "the Corporation" refers to Freedom Environmental Services, Inc., unless the context requires otherwise.
Item 5.02 Removal of Director and Certain Officer;
Effective August 10, 2012, Michael Ciarlone was placed on paid administrative leave and removed from the Board of Directors by a majority vote of the Board of Directors.
Effective August 13, 2012 Michael Ciralone terminated for cause related to the misappropriation of company funds and for attempting to place the company in Bankruptcy after being dismissed as an officer and director of the company.
http://ih.advfn.com/p.php?pid=nmona&article=52457158
http://www.bizjournals.com/southflorida/prnewswire/press_releases/Florida/2012/05/17/SF09237
Freedom Environmental Services releases 10-K for year-end 2011 showing a 159% increase in Revenue over 2010
....
Form 8-K for FREEDOM ENVIRONMENTAL SERVICES, INC.
23-Mar-2012
Changes in Registrant's Certifying Accountant
Item 4.01 Change in Registrant's Auditors
(a) Previous independent registered audit firm.
Effective February 9, 2012, the Registrant dismissed GBH CPAs, which did audit Registrant's year-end financial statements and also performed a review of the last three quarterly financial statements. The change in the Registrant's auditors was recommended and approved by the Board of Directors of the Registrant.
During the period October 14, 2010 through the date of the termination (February 9, 2012) of GBH CPAs there have been no disagreements with GBH, CPAs (as defined in Item 304(a)(1)(iv) of Regulation S-K) on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of GBH CPA's, would have caused them to make reference thereto in their report on financial statements for such years.
The Registrant provided GBH CPAs with a copy of the February 24, 2012 Report on Form 8-K, and requested that GBH CPAs furnish the Registrant with a letter addressed to the U.S. Securities and Exchange Commission stating whether GBH CPAs agrees with the disclosure contained in this report, or, if not, stating the respects in which it does not agree. The Registrant has received a responsive letter from GBH CPAs refusing this request and GBH CPAs letter has raised a fee dispute with the Registrant. Registrant denies owing fees to GBH CPAs but Registrant acknowledges that a fee dispute does now exist as GBH CPAs have attempted to charge Registrant four times the agreed upon fee for services as outlined in Registrant's retainer letter with GBH CPAs.
On February 27, 2012, the Registrant received a copy of an Exhibit 16 letter from its former auditors GBH, CPAs which GBH, CPAs sent to the SEC. A copy of said letter is attached hereto as Exhibit 16.
GBH, CPAs report on the financial statements for the past year did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. There was no uncertainty as to Registrant's ability to continue as a going concern. However, GBH, CPAs has stated that is has withdrawn its audit report on the financial statements as of December 31, 2010 due to a claim for outstanding fees due for services. Registrant disputes such fee claim.
(b) New independent registered public accounting firm.
On February 9, 2012, and effective the same date, on the recommendation of the Registrant's Board of Directors, the Registrant engaged Tarvaran, Askelson & Company, as its independent registered audit firm to audit the Registrant's financial statements for the fiscal year ended December 31, 2011 and to perform procedures related to the financial statements included in the Registrant's quarterly reports on Form 10-Q, beginning with the quarter ending March 31, 2012.
During the fiscal year ended December 31, 2010 and through the date of the engagement of Tarvaran, Askelson & Company, neither the Registrant nor anyone on its behalf has consulted with Tarvaran, Askelson & Company, regarding either:
(a) The application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrant's financial statements, and neither was a written report provided to the Registrant nor was oral advice provided that Tarvaran, Askelson & Company, concluded was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing, or financial reporting issue; or
(b) Any matter that was either the subject of a disagreement or a reportable event, as each term is defined in Items 304(a)(1)(iv) or (v) of Regulation S-K, respectively.
Since 10 or 12 years i buy.
Buy, RS, lost, buy, RS, lost, buy and at least
the price ended in nirvana and Encompass Holdings too.
Thank you all who did this and write "Dedicated to Building Value"! Only lies? It seems so.
http://www.encompassholdings.com/news.html
And the blog, only lies? It seems so.
http://ecmh.wordpress.com/
Who is doing those? May they sleep good?
I think the world will be better soon and such people
goes to another Planet.
Do you think, you are welcome in a better world?
Has anybody answers, what happens the next time with
shareholders of Encompass Holdings, Inc.?
All my hope burst. I am broke.
On never see again.
50,000 USD lost because of such humans. I thank all, which participated.
We have been working quietly and diligently to get the company back on track and bring value to our shareholders. We look forward to the transformation of Millenia Hope into a vibrant and viable company with new goals and objectives.
We have been working in collaboration with other pharmaceutical and nutraceutical companies and positive results are on the horizon. We expect to post our financial statements shortly and make the company OTC current in its financial disclosures.
http://stockvest.com/gbiq.html
http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=GBIQ:US
"Global Biotech Corp., a development stage company, involves in bottled water business. The company was formerly known as Sword Comp-Soft Corp. It was founded in 1998 and is based in Toronto, Canada. Global Biotech Corp. operates as a subsidiary of Millenia Hope Inc."
http://biz.yahoo.com/e/100819/cctr.ob10-q.html
Form 10-Q for CHINA CRESCENT ENTERPRISES, INC.
19-Aug-2010
Quarterly Report
"Plan of Operations:
In March 2010, we executed a non-binding letter of intent (the "Fonix LOI") under which CLPTEC, our wholly-owned subsidiary based in Shanghai, China, would acquire 100% of Shanghai Gaozhi Software Systems, Ltd. ("Gaozhi"), a telecommunications software developer, from Fonix Corporation ("Fonix") in exchange for the issuance of a newly authorized series of preferred stock, the terms and conditions of which are subject to negotiation. The transaction is subject to the parties successfully entering into a definitive agreement. It is anticipated that this transaction will close in the third quarter of 2010. " ...
http://www.fonix.com/
Fonix is still operating. As you know it owns Fonix Speech, Inc., and G-Soft Inc., the parent of GaozhiSoft. Fonix Speech continues to generate revenues and delivers it's speech software to OEMs and game software developers. In November 2010 THQ released Wheel of Fortune and Jeopardy--two games with Fonix Speech. Management of Gaozhisoft has been a problem and has not provided US GAAP financial statements which has caused significant harm to Fonix. Without these financials, Fonix Corporation has not filed 2009 10-K and 2010 10-Qs. The Company has taken direct legal action and expects to have the issue resolved, however, we cannot speculate when the problem will be resolved sufficient to prepare and release consolidated financial statements.
All yoe say, write, think, comes back to you.
I am a board priest, you think?
No, it is the law of the life.
People, who wish other people bad, do not certainly come into the heaven. It is worthwhile to think about this.
"...
Aqua currently has commitments for 1,100 XBoards from various dealers. Based on the reaction we’ve gotten so far, we expect most of the new contacts to carry an inventory of XBoards in their stores.
In addition to the watercraft dealers, we’ve been contacted about Aqua producing a Private Label XBoard. If Aqua agrees, this company will commit to purchase a minimum of 2,500 XBoards to be delivered as fast as they can be produced.
..."
http://www.encompassholdings.com/press-releases/PR-020310-XBoard.pdf